Clinical trials: Psoriatic-arthritis
Arthritis, Rheumatoid, Spondylarthropathies
Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening?
Pain management is rated by patients with inflammatory arthritis as the highest priority in their disease treatment. Past research showed that music therapy is associated with reduced pain and depression.
- Conditions
- Arthritis, Rheumatoid, Spondylarthropathies, Arthritis, Psoriatic, Inflammatory Arthritis
- Trial name
- NCT02436785
- Testing
- Music Therapy, Music Listening
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University of British Columbia
Subclinical Psoriatic Arthritis
A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis
Psoriatic arthritis (PsA) is one of the most common comorbidities in patients with psoriasis (PsO). Current research suggests that the progression from PsO to PsA can be divided into five stages of the disease: PsO, preclinical…
- Trial name
- NCT06686082
- Testing
- Biologics
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chao Ji
Arthritis, Psoriatic
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
- Trial name
- STAR (NCT04929210)
- Testing
- Guselkumab
- Where
- 242 sites in United States, Argentina and 24 more
- Volunteers
- 411 people
- Sponsor
- Janssen Research & Development, LLC
Ankylosing Spondylitis, Autoimmune Disease
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs.
- Conditions
- Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis
- Trial name
- NCT04751396
- Testing
- Best Practice, Educational Intervention, Interview
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- M.D. Anderson Cancer Center
Juvenile Idiopathic Arthritis
A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.
- Trial name
- JUVE-BASIS (NCT03773978)
- Testing
- Baricitinib
- Where
- 86 sites in Argentina, Australia and 18 more
- Volunteers
- 220 people
- Sponsor
- Eli Lilly and Company
Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
This was a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic…
- Trial name
- NCT03031782
- Testing
- secukinumab
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis
The purpose of this study is to determine if Infliximab is safe and effective in the treatment of psoriatic arthritis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of…
- Trial name
- NCT00051623
- Testing
- Infliximab
- Volunteers
- 70 people
- Sponsor
- Centocor, Inc.
Psoriatic Arthritis
Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA
Methotrexate (MTX) co-medication can improve the therapeutic effect of biological therapies (e.g. Tumor necrosis factor (TNF) -inhibitors) in rheumatoid arthritis (RA), but its role in Psoriatic Arthritis (PsA) remains unclear.
- Trial name
- MUST (NCT03148860)
- Testing
- Methotrexate, Ustekinumab
- Where
- Germany
- Volunteers
- 186 people
- Sponsor
- Dr. Frank Behrens
Psoriatic Arthritis
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3…
- Trial name
- INVIGORATE 2 (NCT04209205)
- Testing
- AIN457 6 mg/kg i.v., AIN457 3 mg/kg
- Where
- 80 sites in United States, Brazil and 13 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Psoriatic Arthritis
Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents
An observational study investigating the utilisation and effectiveness of originator and biosimilar anti-TNF agents in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT03470688
- Testing
- Originator, Biosimilar
- Where
- 22 sites in Australia
- Volunteers
- 5,000 people
- Sponsor
- Opal Rheumatology Ltd.
Psoriatic Arthritis
A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis
This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with moderately to severely active Psoriatic Arthritis (PsA) who have an inadequate response or are intolerant to conventional disease-modifying…
- Trial name
- EQUATOR (NCT03101670)
- Testing
- filgotinib
- Where
- 25 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 131 people
- Sponsor
- Lakefront Biotherapeutics NV
Psoriatic Arthritis
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.
- Trial name
- NCT04957550
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen
Arthritis, Psoriatic
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
The purpose of this study is to evaluate the effectiveness (improvement of signs and symptoms) and safety of ustekinumab in participants with active psoriatic arthritis.
- Trial name
- NCT01009086
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 102 sites in United States, Australia and 12 more
- Volunteers
- 615 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Interval Training Study in Psoriatic Arthritis
Psoriatic arthritis is a chronical inflammatory disease characterized by pain and reduced physical function. Patients have a higher risk of cardiovascular disease and a higher body mass index.
- Trial name
- NCT02995460
- Testing
- interval training
- Volunteers
- 67 people
- Sponsor
- Norwegian University of Science and Technology
Psoriatic Arthritis
Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis
Title Safety and Efficacy of Tofacitinib vs Methotrexate in the treatment of Psoriatic Arthritis- An Open Label Randomized single center study Psoriatic arthritis is defined as an inflammatory arthropathy associated with skin…
- Trial name
- PsOLSET-BD (NCT03736161)
- Testing
- Group A- Tofacitinib, Group B- Methotrexate
- Where
- Bangladesh
- Volunteers
- 61 people
- Sponsor
- Globe Pharmaceuticals Limited
Rheumatoid Arthritis, Psoriatic Arthritis
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
This is a five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab).
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- ProAct (NCT01078558)
- Volunteers
- 5,940 people
- Sponsor
- AbbVie (prior sponsor, Abbott)